Neuraxis, Inc. (NRXS) vs Rallybio Corporation (RLYB)

Neuraxis, Inc. and Rallybio Corporation are both Biotechnology companies. Neuraxis, Inc. and Rallybio Corporation are of similar size ($86.2M and $85.6M). Neuraxis, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 3.3×. Neuraxis, Inc. grew revenue faster over the last twelve months: 65.2% against 1.18%. Rallybio Corporation has the higher net margin (0.00% vs −159.0%) and the lower return on invested capital (−944.4% vs 0.00%). Across the 16 metrics below, Rallybio Corporation leads on 12 and Neuraxis, Inc. on 4.

Valuation

Metric NRXS RLYB Biotechnology median
P/E n/m 3.35 10.26
P/S 13.79 104.84 9.18
P/B 10.89 0.97 2.05
Price to free cash flow n/m 2.91 24.81
EV/EBITDA n/m 0.03 0.65
EV/Sales 12.23 (0.86) 8.98
Earnings yield (12.89%) 29.87% (34.89%)
Free cash flow yield (7.88%) 34.41% (24.52%)

Profitability

Metric NRXS RLYB Biotechnology median
Gross margin 85.56% 100.00% 65.16%
Operating margin (144.51%) 0.00% 0.00%
Net margin (159.01%) 0.00% 0.00%
Free cash flow margin (106.10%) 0.00% 0.00%
Return on equity (153.96%) 34.52% (50.12%)
Return on assets (98.96%) 32.85% (45.60%)
Return on invested capital 0.00% (944.36%) 0.00%

Growth

Metric NRXS RLYB Biotechnology median
Revenue growth (TTM) 65.22% 1.18% 6.26%
EPS growth (last fiscal year) 22.13% 85.06% 29.88%
Revenue growth, 5-year CAGR 13.08% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NRXS RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.04 28.87 4.89
Net debt to EBITDA 0.64 1.63 1.01

Dividend

Metric NRXS RLYB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NRXS RLYB Biotechnology median
Market cap 86.15m 85.61m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack